NEW YORK (GenomeWeb) – Owlstone Medical said today it has signed a service agreement with AstraZeneca to study breath-based biomarkers for asthma and COPD.

Under the terms of the agreement, Owlstone will give AstraZeneca access to its Breath Biopsy Services to help the pharmaceutical company identify breath-based biomarkers as well as classification algorithms for the conditions, with the aim of identifying disease phenotypes and the best treatments for those phenotypes.

Financial and other terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.

Mar
14
Sponsored by
BD

In this webinar, Dr. Wendy Béguelin of Weill Cornell Medicine will discuss how she used the BD Rhapsody single-cell RNA-seq platform and YFP floxed reporter mouse models to study how lymphoma-associated mutations disrupt the immune system by affecting GC B-cell states, explaining the biology of initiation of low-grade follicular lymphoma.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.